Inverse agonism at β-adrenergic receptors: therapeutic implications

References

• Neher E, Sakmann B. Single channel currents recorded from membrane of denervated frog muscle fibers. Nature 260, 799–802 (1976).
   PubMed Web of Science ®Google Scholar
• Cerione RA, Regan JW, Nakata H et al. Functional reconstitution of the alpha 2-adrenergic receptor with guanine nucleotide regulatory proteins in phospholipid vesicles. j Biol. Chem. 261, 3901–3909 (1986).
   Google Scholar
• •One of the pionering studies indicating agonist independent interaction of GPCRs with G-protein.
   Google Scholar
• Murray R, Keenan AK. The beta- adrenoceptor is precoupled to Gs in chicken erythrocyte membranes. Cell Signal. 1,173–179 (1989).
   PubMed Web of Science ®Google Scholar
• Costa T, Herz A. Antagonists with negative intrinsic activity at 8—opioid receptors coupled to GTP-binding proteins. Proc. Natl Acad. Sci. USA 86,7321–7325 (1989).
   Google Scholar
• •First study describing the concept of negative efficacy at GPCRs.
   Google Scholar
• Ligt RA, Kourounakis AP, Uzerman AR Inverse agonism at G-protein coupled receptors: (patho)physiological relevance and implications for drug discovery. Br. Pharmacol 130,1–12 (2000).
   PubMed Web of Science ®Google Scholar
• •• A good review about inverse agonism at GPCRs and its relevance with pathophysiologies.
   Google Scholar
• Ariens EJ. Affinity and intrinsic activity in the theory of competitive inhibition. Part I. Problems and theory. Arch. Int. Pharmacodyn. Ther 99,32–49 (1954).
   PubMedGoogle Scholar
• Stephenson RP. A modification of receptor theory. Br. Pharmacol 11,379–393 (1956).
   PubMed Web of Science ®Google Scholar
• Del Castillo J, Katz B. Interaction at end- plate receptors between different choline derivatives. Proc. I?. Soc. Lond. (Biol. Sci) 146,369–381 (1957).
   PubMed Web of Science ®Google Scholar
• De Lean A, Stadel JM, Lefkowitz RJ. A ternary complex model explains the agonist-specific binding properties of the adenyl cyclase-coupled 13-adrenergic receptor. j Biol. Chem. 255,7108-7117 (1980).
   Google Scholar
• Onaran HO, Costa T, Rodbard D. 13y Subunits of guanine nucleotide-binding proteins and regulation of spontaneous receptor activity: thermodynamic model for the interaction between receptors and guanine nucleotide-binding protein subunits. Ma. Pharmacol 43,245–256 (1993).
   Google Scholar
• Samama P, Cotecchia S, Costa T, Lefkowitz RJ. A mutation-induced activated state of the 132-adrenergic receptor: Extending the ternary complex model.," Biol. Chem. 268, 4625–4636 (1993).
   Google Scholar
• ••An important study in which an activatedmutant of I32AR was produced and the active and inactive state of GPCRs proposed.
   Google Scholar
• Weiss J, Morgan PH, Lutz MW, Kenakin TP. The cubic ternary complex receptor-occupancy model III. Resurrecting efficacy. Theor. Biol. 181,381–397 (1996).
   PubMed Web of Science ®Google Scholar
• Onaran HO et al. A look at receptor efficacy. From the signaling network of the cell to the intramolecular motion of the receptor. In: The Pharmacology of Functional. Biochemical and Recombinant Systems Handbook of Experimental Pharmacology, Kenakin TP, Angus JA, (Ed.) Springer, 48,217-280 (2000).
   Google Scholar
• Gilman A. Regulation of adenyl cyclase by G-proteins, In: The Biology and Medicine of Signal Transduction. Nishizuka Y (Ed.), Raven Press, New York, USA 51–57 (1990).
   Google Scholar
• Birnbaumer L. Receptor to effector signaling through G-proteins: Roles for fry dimers as well as a subunits. Ce1171, 1069–1072 (1992).
   Google Scholar
• Xiao RP, Lakatta EG. 131-Adrenoceptor stimulation and 132-adrenoceptor stimulation differ in their effects on contraction, cytosolic Ca2+ and Ca2+ current in single rat ventricular cells. Circ. Res. 73,286-300 (1993).
   Google Scholar
• Zhou YY, Cheng H, Bogdanov KY et al. Localized cAMP-dependent signaling mediates 132-adrenergic modulation of cardiac excitation-contraction coupling. Am. Physiol 273, H1611—H1618 (1997).
   Google Scholar
• Dzimiri N. Regulation of signaling in cardiac function and disease. Pharmacol Rev 51,465–501 (1999).
   PubMed Web of Science ®Google Scholar
• ••A good review about DAR and cardiac functions and diseases.
   Google Scholar
• Freissmuth M, Selzer E, Marullo S, Schutz W, Strosberg AD. Expression of two human beta-adrenergic receptors in Escherichia coli:functional interaction with two forms of the stimulatory G-protein. Proc. Natl Acad. Sci. USA 88,8548–8552 (1991).
   Google Scholar
• Samama P, Gang P, Costa T, Cotecchia S, Lefkowitz RJ. Negative antagonists promote an inactive conformation of the 132-adrenergic receptor. Md. Pharm. 45, 390–394 (1993).
   Google Scholar
• Chidiac P, Hebert TE, Valquette, Dennis M, Bouvier M. Inverse agonist activity of 13-adrenergic antagonists. Ma. Pharm. 45, 490–499 (1993).
   Google Scholar
• •One of the first studies showing inverse agonistic efficacies of I3AR antagonists at I32AR.
   Google Scholar
• Adie EJ, Milligan G. Regulation of basal adenyl cyclase activity in neuroblastoma x glioma hybrid, NG108-15, cells transfected to express the human beta 2 adrenoceptor: evidence for empty receptor stimulation of the adenyl cyclase cascade. Biochem. J. 303, 803–804 (1994).
   Google Scholar
• Mewes T, Dutz S, Ravens U, Jakobs KH. Activation of calcium currents in cardiac myocytes by empty beta-adrenoceptors. Circulation 88,2916–2922 (1993).
   PubMed Web of Science ®Google Scholar
• Gotze K, Jakobs KH. Unoccupied beta- adrenoceptor-induced adenyl cyclase stimulation in turkey erythrocyte membranes. Eur. j Pharmacol 268,151–158 (1994).
   PubMed Web of Science ®Google Scholar
• Varma DR, Shen H, Deng XF, Pen KG, Chemtob S, Mulay S. Inverse agonist activities of 13-adrenoceptor antagonists in rat myocardium. Br. j Pharmacol 127, 895–902 (1999).
   Google Scholar
• Milano CA, Allen F, Rockman HA et al. Enhanced myocardial function in transgenic mice overexpressing the 132-adrenergic receptor. Science 264,582–586 (1994).
   PubMed Web of Science ®Google Scholar
• Bond RA, Leff P, Johnson TD et al Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of 132-adrenoceptor. Nature 374,272–276 (1995).
   PubMed Web of Science ®Google Scholar
• •An interesting and pioneer study showing inverse agonism at I32ARs in transgenic animal models.
   Google Scholar
• Garda]. H, Bond RA, Johnson MD, Friedman E, Onaran HO. An efficacy-dependent effect of cardiac overexpression of 132-adrenoceptor on ligand affinity in transgenic mice. MoL Pharm. 52, 187–194 (1997).
   Web of Science ®Google Scholar
• Onaran HO, Gurdal H. Ligand efficacy and affinity in an interacting 7TM receptor model. Trends PharmacoL Sci. 20, 279–286 (1999).
   PubMed Web of Science ®Google Scholar
• Engelhardt S, Grimmer Y, Fan GH, Lohse MJ. Constitutive activity of human 01-adrenergic receptor in 3l-receptortransgenic mice. MoL PharmacoL 60, 712–717 (2001).
   PubMed Web of Science ®Google Scholar
• •This study shows constitutive activity of 131AR and inverse agonistic efficacies of DAR antagonists at 131AR.
   Google Scholar
• Maack C, Cremers B, Flesch M, Hoper A, Sudkamp M, Bohm M. Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. Br. PharmacoL 130, 1131–1139 (2000).
   PubMed Web of Science ®Google Scholar
• ••One of the first studies showing inverseagonistic actions of DAR antagonists at DiAR in human myocardium. It also indicates posible role of the inverse agonism in the therapeutical effectiviness of these drugs in the heart failure.
   Google Scholar
• Maack C, Tyroller S, Schnabel P et al. Characterization of beta (1)-selectivity, adrenoceptor-G(s)-protein interaction and inverse agonism of nebivolol in human myocardium. Br. J. PharmacoL 132(8),1817–1826 (2001).
   Google Scholar
• ••This study shows inverse agonistic actionsof DAR antagonists at 131AR in human myocardium. It also indicates possible role of the inverse agonism in the therapeutical effectiviness of these drugs in the heart failure.
   Google Scholar
• Herzig MC, Chapman WG, Sheridan A, Rake JB, Woynarowski JM. Neurotensin receptor-mediated inhibition of pancreatic cancer cell growth by the neurotensin antagonist SR 48692. Anticancer Res. 19, 213–219 (1999).
   Google Scholar
• Rosenkilde MM, Schwartz TW. Potency of ligands correlates with affinity measured against agonist and inverse agonists but not against neutral ligand in constitutively active chemokine receptor. MoL Pharmacol 57(3), 602–609 (2000).
   PubMed Web of Science ®Google Scholar
• Kenakin TP. Inverse, protean and ligand- selective agonism: Matters of receptor conformation. FASEB J. 15, 598–611 (2001).
   PubMed Web of Science ®Google Scholar
• Cal G, Gurdal H, Smith C, Wang HY, Friedman E. Inverse agonist properties of dopaminergic antagonists at the D la dopamine receptor: Uncoupling of the Dla dopamine receptor from Gs protein. MoL Pharm. 56, 989–996 (1999).
   Web of Science ®Google Scholar
• Herrick-Davis K et al. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J. PharmacoL Exp. Ther. 295, 226–232 (2000).
   Google Scholar
• Meneses A. Could the 5-HT1B receptor inverse agonism affect learning consolidation? Neurosci. Biobehav. Rev 25, 193–201 (2001).
   Google Scholar
• Strange PG. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. PharmacoL Rev 53, 119–133 (2001).
   PubMed Web of Science ®Google Scholar
• Spiegel AM. Mutations in G-proteins and G-protein coupled receptors in endocrine disease Clin. EndocrinoL Metab. 81, 2434–2442 (1996).
   Google Scholar
• Chattopadhyay N. Biochemistry, physiology and pathophysiology of the extracellular calcium-sensing receptor. Int. Biochem. Cell BioL 32, 789–804 (2000).
   PubMed Web of Science ®Google Scholar
• Mannstadt M, Juppner H, Gardella TJ. Receptors for PTH and PTHrP: their biological importance and functional properties. Am. I PhysioL 277, F665-675 1999).
   Google Scholar
• Nagaraja S, Iyer S, Liu X, Eichberg J, Bond RA. Treatment with inverse agonists enhances baseline atrial contractility in transgenic mice with chronic 132-adrenoceptor activation Br. J. PharmacoL 127, 1099–1104 (1999).
   Google Scholar
• Lentes K-U, Berrettini WH, Hoehe MR, Chung F-Z, Gershon ES. A biallelic DNA polymorphism of the human 132-adrenergic receptor detected by Ban I-Adrbr-2. Nucleic Acids Res. 16, 2359 (1988)
   Google Scholar
• Svetkey LP, Chen Y-T, McKeown SP, Preis L, Wilson AE Preliminary Evidence of Linkage of Salt Sensitivity in Black Americans at the 132-Adrenergic Receptor Locus. Hypertension 29, 918–922 (1997).
   PubMed Web of Science ®Google Scholar
• Liggett SB. Pharmacogenetics of beta-1- and 13-2-adrenergic receptors. Pharmacology 61, 167–173 (2000).
   PubMed Web of Science ®Google Scholar
• Zuscik MJ, Porter JE, Gaivin R, Perez DM. Identification of a conserved switch residue responsible for selective constitutive activation of the 132-adrenergic receptor. BioL Chem. 273, 3401–3407 (1998).
   Web of Science ®Google Scholar
• Can A, Sayar K, Friedman E, Ambrosio C, Erdemli E, Garda]. H. The effects of agonist stimulation and 132-adrenergic receptor level on subcellular distribution of Gs alpha protein. Cellular Signalling12, 303–309, (2000).
   Google Scholar
• Burstain ES, Spalding TA, Brann MR. Pharmacology of muscarinic receptor subtypes constitutively activated by G-proteins. MoL Pharmacol 51, 312–319 (date).
   Google Scholar
• Meij JT Regulation of G-protein function: implications for heart disease. MoL Cell Biochem. 157, 31–38 (1996).
   PubMed Web of Science ®Google Scholar
• Bushman WD, Wilson LK, Luttrell DK, Moyers JS, Parsons SJ. Overexpression of c-src enhances 13-adrenergic-induced cAMP accumulation. Proc. Nat/Acad. Sci. USA 87, 7462–7466 (1990).
   Google Scholar
• Magnusson Y, Marullo S, Hoyer S et al. Mapping of a functional autoimmune epitope on the 13–1 adrenergic receptor in patients with idiopatic dilated cardiomyopathy. j Clin. Invest. 86, 1658–1663 (1990).
   Google Scholar
• Guillet JG, Lengagne R, Magnusson Y, Tate K, Strosberg AD, Hoebeke J. Induction of a pharmacologically active clonotypic B-cell response directed to an immunogenic region of the human 13–2 adrenergic receptor. Clin. Exp. ImmunoL 89, 461–467 (1992).
   Google Scholar
• Eng H, Magnusson Y, Matell G, Lefvert AK, Saponja R, Hoebke J. 3-2 adrenergic receptor antibodies in myasthenia gravis. Autoimmun. 5, 213–227 (1992).
   Web of Science ®Google Scholar
• Chiale PA, Rosenbaum MB, Elizari MV et al High prevalence of antibodies against 13 1-and 13 2-adrenoceptors in patients with primary electrical cardiac abnormalities. J. Am. Coll. Cardiol 26, 864–869 (1995).
   Google Scholar
• Mijares A, Lebesgue D, Argibay J, Hoebeke J. Antipeptide antibodies sensitive to the active state of the 132-adrenergic receptor. FEBS lett. 399, 188–191 (1996).
   PubMed Web of Science ®Google Scholar
• MacEwan DJ, Milligan G. Inverse agonist-induced upregulation of the human 132-adrenoceptor in transfected neuroblastoma X glioma hybrid cells. MoL Pharmacol. 50, 1479–1486 (1996).
   PubMed Web of Science ®Google Scholar
• •Compares the effect of DAR antagonists on 132AR level in the cell lines.
   Google Scholar
• Milligan G, Bond RA. Inverse agonism and the regulation of receptor number. Trends PharmacoL Sci. 18,468–474 (1997).
   PubMed Web of Science ®Google Scholar
• Yamada S, Ohkura T, Uchida S et al A sustained increase in beta-adrenoceptors during long-term therapy with metoprolol and bisoprolol in patients with heart failure from idiopathic dilated cardiomyopathy. Life Sci. 58,1737–1744 (1996).
   PubMed Web of Science ®Google Scholar
• ••Indicates the correlation between restoration in I32AR density and improvement in the heart failure by treatment with antagonists with inverse agonistic properties.
   Google Scholar
• Fowler MB. Controlled trials with beta blockers in heart failure: metoprolol as the prototype. Am.j CardioL 71 (9), 45C-53C (1993).
   Google Scholar
• Wiliam RN, Aiyar N, Yue TL et aL In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats. J PharmacoL Exp. Ther. 289,48–53 (1999).
   PubMed Web of Science ®Google Scholar
• Bristow MR, Abraham WT, Yoshikawa T et al. Second- and third-generation beta-blocking drugs in chronic heart failure Cardiovasc. Drugs Ther. 11 (Suppl. 1) 291–296 (1997).
   Google Scholar
• Smith AJ, Wehner JS, Manley HJ, Richardson AD, Beal J, Bryant PJ. Current role of beta-adrenergic blockers in the treatment of chronic congestive heart failure. Am. J Health Syst. Pharm. 58, 140–145 (2001).
   PubMed Web of Science ®Google Scholar
• •A good review about the use of PAR antagonists in patients with congestive heart failure.
   Google Scholar
• Hjalmarson A. Cardioprotection with beta- adrenoceptor blockers. Does lipophilicity matter? Basic Res. CardioL 95\(Suppl. 1), 141–45 (2000).
   Google Scholar
• Hash TW, 2nd, Prisant LM. Beta-blocker use in systolic heart failure and dilated cardiomyopathy j Clin. PharmacoL 37,7–19 (1997).
   Web of Science ®Google Scholar
• Rosenkilde MM, Schwartz TW. Potency of ligands correlates with affinity measured against agonist and inverse agonists but not against neutral ligand in constitutively active chemokine receptor. MoL Pharmacol. 57(3), 602–609 (2000).
   Google Scholar
• Freeman K, Lerman I, Kranias EG et al. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. j Clin. Invest. 107,947–948 (2001).
   PubMed Web of Science ®Google Scholar
• Bisognano JD, Weinberger HD, Bohlmeyer TJ et al. Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. j MoL Cell CardioL 32, 817–830 (2000). Affiliation
   Google Scholar